GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...

has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in the treatment of advanced ovarian cancer. The U.K. drugmaker said that ...

along with providing access to new scientific capabilities,” says GSK CEO Emma Walmsley in the release. TESARO’s drug Zejula is a PARP inhibitor approved for treating ovarian cancer. PARP inhibitors ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

UK-based GlaxoSmithKline PLC (GB:GSK) hits a key milestone in its ovarian cancer trial, testing Zejula (niraparib) and Jemperli (dostarlimab). The company announced that its FIRST-ENGOT-OV44 phase ...

GSK has agreed to buy US biopharmaceutical business ... It acquired TESARO, developer of ovarian cancer drug Zejula, for £4billion in 2019 before buying California-based rare cancer specialist ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for 2025. The company steered expectations toward an increase of 3 to 5pc in ...

The safety and tolerability profile was generally consistent with the known safety profiles of the individual agents, GSK said. Zejula is an oral, once-daily poly-ADP ribose polymerase inhibitor ...